<DOC>
	<DOCNO>NCT00003729</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat child relapse refractory acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Relapsed Refractory Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate complete response rate combination fludarabine , idarubicin , cytarabine child relapse refractory acute lymphocytic leukemia . II . Evaluate safety tolerance treatment patient . III . Evaluate time progression , disease free survival , overall survival patient . OUTLINE : This open label , multicenter study . Patients receive idarubicin IV 1 hour day 1-3 . Fludarabine IV administer 30 minute day 1-5 . Cytarabine IV administer 4 hour day 1-5 . If partial response obtain , patient receive second course treatment . Patients receive consolidation course absence disease progression unacceptable toxicity . Idarubicin IV administer 1 hour day 1 2 . Fludarabine IV administer 30 minute , follow cytarabine IV 4 hour day 1-5 . Patients follow every 3 month 2 year death . PROJECTED ACCRUAL : A total 24-45 patient accrue study within 27 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically diagnose relapsed refractory acute lymphocytic leukemia previously treat front line therapy FAB L1 L2 Bone marrow relapse either isolate associated CNS testicular relapse Bone marrow blast cell great 10 % No isolated CNS relapse PATIENT CHARACTERISTICS : Age : Under 18 Performance status : WHO 02 Playperformance scale least 60 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.5 time normal Renal : Creatinine le 2.5 time normal Cardiovascular : No symptom cardiac failure No decline ejection fraction 20 % low limit normal Shortening fraction least 25 % Other : No psychological , familial , sociological geographical condition would hamper compliance No uncontrolled infection PRIOR CONCURRENT THERAPY : At least 6 month since prior autologous bone marrow transplantation No prior allogeneic bone marrow transplantation No concurrent treatment experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
</DOC>